These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38063420)

  • 21. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
    Liu Y; Zhang HX; Su J; Geng QC; Lin X; Feng CX
    Acta Haematol; 2023; 146(3):173-184. PubMed ID: 36572014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
    Kuter DJ; Newland A; Chong BH; Rodeghiero F; Romero MT; Pabinger I; Chen Y; Wang K; Mehta B; Eisen M
    Br J Haematol; 2019 May; 185(3):503-513. PubMed ID: 30793285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study.
    Guillet S; Crickx E; Azzaoui I; Chappert P; Boutin E; Viallard JF; Rivière E; Gobert D; Galicier L; Malphettes M; Cheze S; Lefrere F; Audia S; Bonnotte B; Lambotte O; Noel N; Fain O; Moulis G; Hamidou M; Gerfaud-Valentin M; Marolleau JP; Terriou L; Martis N; Morin AS; Perlat A; Le Gallou T; Roy-Peaud F; Robbins A; Lega JC; Puyade M; Comont T; Limal N; Languille L; Zarrour A; Luka M; Menager M; Belmondo T; Hue S; Canoui-Poitrine F; Michel M; Godeau B; Mahévas M
    Blood; 2023 Jun; 141(23):2867-2877. PubMed ID: 36893453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
    Gudbrandsdottir S; Frederiksen H; Hasselbalch H
    Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.
    Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R
    Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
    Li T; Liu Q; Pu T; Liu J; Zhang A
    Expert Opin Pharmacother; 2023 Apr; 24(6):763-774. PubMed ID: 37010022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China.
    Mei H; Zhou H; Hou M; Sun J; Zhang L; Luo J; Jiang Z; Ye X; Xu Y; Lu J; Wang H; Hui A; Zhou Y; Hu Y
    Res Pract Thromb Haemost; 2023 Aug; 7(6):102158. PubMed ID: 37700877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany.
    Reiser M; Josten KM; Dietzfelbinger H; Seesaghur A; Schill M; Hippenmeyer J; Welslau M
    Acta Haematol; 2022; 145(4):394-403. PubMed ID: 34959233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China.
    Cheng X; Wang Z; Dong S; Ma J; Meng J; Wang X; Wu R
    Br J Haematol; 2023 Aug; 202(3):636-644. PubMed ID: 37188335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience.
    Crickx E; Ebbo M; Rivière E; Souchaud-Debouverie O; Terriou L; Audia S; Ruivard M; Asli B; Marolleau JP; Méaux-Ruault N; Gerfaud-Valentin M; Audeguy P; Hamidou M; Corm S; Delbrel X; Fontan J; Lebon D; Mausservey C; Moulis G; Limal N; Michel M; Godeau B; Mahévas M
    Br J Haematol; 2023 Aug; 202(4):883-889. PubMed ID: 37247631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia.
    Grainger J; Bussel J; Tarantino M; Cooper N; Beam D; Despotovic J; Maschan A; Wang K; Eisen M; Bowers C
    Blood Adv; 2023 Feb; 7(3):396-405. PubMed ID: 35413092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.